CDBKFCLOUDBREAK PHARMA INC.

About CLOUDBREAK PHARMA INC. (CDBKF)

CLOUDBREAK PHARMA INC. (CDBKF) is a company headquartered in Kowloon, HK, China whose shares trade over-the-counter on the Pink tier.

Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease. It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema.

CDBKF key facts

Ticker symbol

CDBKF

Market tier

Pink

Headquarters

Kowloon, HK, China

Shares outstanding

844,565,892

Reporting standard

International Reporting: Hong Kong Stock Exchange

Audit status

Not Available

Fiscal year end

12/31

Explore more: Pink stocks · OTC stocks starting with C